# Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia

> **NCT02816112** · PHASE4 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 458 (actual)

## Conditions studied

- Early Stage Breast Cancer

## Interventions

- **DRUG:** Ciprofloxacin
- **DRUG:** Neupogen

## Key facts

- **NCT ID:** NCT02816112
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2020-03
- **Final completion:** 2020-04
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02816112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02816112, "Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02816112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*